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Summary
Primary Hypercalciuria (PH) is very frequently accompanied by
some degrees of bone demineralization. The most frequent clin-
ical condition in which this association has been studied is cal-
cium nephrolithiasis. In these patients bone density has been
reported to be very frequently low and increased susceptibility
to fragility fractures has been described. One of the most im-
portant aspects is the very poor definition of this bone disease
from a histomorphometric point of view. At present, the most
common findings seem to range from those of a low bone
turnover condition to an osteomalacic trait. Many factors are in-
volved in the complex relationships between bone loss and PH.
Since bone loss has been mainly reported in patients with fast-
ing hypercalciuria, a primary alteration in bone metabolism has
been proposed as a cause of both hypercalciuria and bone
demineralization. This hypothesis has been strengthened by
the observation that some bone resorbing-cytokines, such as
IL-1, IL-6, and TNF- are elevated in hypercalciuric patients. The
effect of an excessive response to the acid load induced by di-
etary protein intake seems an additional factor explaining a
primitive alteration of bone. The intestine plays a major role in
the clinical course of bone disease in PH. Patients with absorp-
tive hypercalciuria less frequently show bone disease and a re-
duction in dietary calcium greatly increases the probability of
bone loss in PH subjects. It has recently been reported that
greater bone loss is associated with a larger increase in intesti-
nal calcium absorption in PH patients. Considering the absence
of PTH alterations, it has been proposed that this is not a com-
pensatory phenomenon, but probably the marker of disturbed
cell calcium transport, involving both intestinal and bone tis-
sue. While renal hypercalciuria is rather uncommon, the kidney
still seems to play a role in the pathogenesis of bone loss of PH
patients, possibly via the effect of mild to moderate urinary
phosphate loss, with secondary hypophosphatemia. In conclu-
sion, bone loss is very common among PH patients. Even if
most of the factors involved in this process have been identi-
fied, many aspects of this intriguing clinical condition remain to
be elucidated.
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Primary (or idiopathic) hypercalciuria (PH) is the most frequent
metabolic abnormality in patients with nephrolithiasis (1) and it
is believed to be present in up to 10% of the general population
(2). Several hypotheses have been made to explain its patho-
genesis and clinical consequences. It has recently become
clear that bone is one of the most important involved tissues in
patients with PH. Our paper will focus on the role of bone in hy-
percalciuric patients.
The size of the problem
Since the seventies, the hypothesis that a continuous elevation
in urine calcium excretion could be associated with some de-
gree of bone loss has been more clearly defined. Due to the
fact that idiopathic hypercalciuria is one of the most common
phenotypes in patients with kidney stones, the large majority of
the studies undertaken to assess bone status in hypercalciuric
patients were conducted in patient with calcium nephrolithiasis.
These studies demonstrated that while bone density is sub-
stantially normal or only slightly reduced in patients with calci-
um nephrolithiasis without hypercalciuria, significant bone loss
is present in patients with kidney stones and primary hypercal-
ciuria (Table I). Bone loss seems to mainly involve those skele-
tal sites where trabecular bone is more represented, such as
vertebral bodies (5-14,16,17). However, a reduction in femoral
density was reported by several authors (9,10,12-14,16,17).
There are no data available on the number of hypercalciuric
patients who suffer from an established osteoporotic bone dis-
ease, as defined by WHO classification (18). Yet, the rate of
demineralization is generally substantial, ranging from 10 to
15% as compared to age and sex-matched normal subjects
(5,7-9,12,14). Some authors reported even more significant de-
creases in bone density (6). These results seem to be of clini-
cal importance, in view of the relatively young age (approxi-
mately 50 years) and of the large proportion of males in the
populations studied. There are no data on hypercalciuria as a
risk factor for fractures. However, an increased fracture risk
was reported in patients with renal calculi (19). Since bone loss
was predominantly, if not exclusively, reported in patients with
kidney stones and hypercalciuria, exaggerated urine calcium
excretion is likely to increase the probability of developing frac-
tures. 
Besides the wide overlap between the pathophysiology of ab-
sorptive and fasting hypercalciuria, there is some doubt about
the differences in bone involvement in patients with both forms
of hypercalciuria. While most authors specifically observed a
significant proportion of bone loss in patients with fasting hy-
percalciuria but not in those with the absorptive form (5-
7,12,14), others reported a decrease in bone density irrespec-
tive of the type of primary hypercalciuria (8,10,11), that is, even
in patients classified as having absorptive hypercalciuria (8-
10). These data could appear rather surprising, if one consid-
ers that patients with the absorptive form of hypercalciuria
should be theoretically protected from bone loss by the same
mechanism generating hypercalciuria, that is, increased intesti -
nal calcium absorption, which in turn induces positive calcium
balance. However, several explanations can be proposed. For
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one thing, some studies focusing on this issue were carried out
on too small population samples to properly differentiate the ef -
fect on bone of the two forms of hypercalciuria (10).
Pietschmann et al. (8) found that their patients with absorptive
hypercalciuria had low bone density, although its prevalence
was limited as compared to patients with fasting hypercalciuria.
They speculated on the hypothesis that a low calcium diet,
aimed to prevent stone recurrence, and a high consumption of
dietary protein may be additional risk factors for bone loss in
absorptive hypercalciuria. Moreover, increased serum levels of
calcitriol or increased sensitivity to this hormone may stimulate
bone resorption in these patients. More recently, it has been
found that hypercalciuric patients with the largest proportion of
bone loss also present the highest levels of intestinal calcium
absorption (17). These intriguing findings suggest that a unique
disorder may account for both bone and intestinal alterations,
thus explaining the reason why bone loss can be observed in
both forms of hypercalciuria. 
The type of bone disease
One of the most puzzling aspects of bone disease in patients
with PH is its nature. As a matter of fact, bone histomorphome-
tric studies are rare in this setting and have yielded non-homo-
geneous results. Bone resorption activity seems to be in-
creased (31,32,34) or even normal (33), while the most com-
mon histological alteration is a reduction in bone formation
function, as observed by most authors (31-36). These results
tend to be in contrast with those reported for bone turnover
markers. Most authors observed increased levels of both bone
formation and resorption markers in hypercalciuric patients (5-
7,12,14,21). Additional uncertainness may arise from the ob-
servation of a moderate to severe mineralization defect, asso-
ciated with a prolonged mineralization lag (31,33,34,36). An in-
creased osteoid thickness was also reported by Thomas and
coworkers (35). Because of the differences in the populations
studied (type of PH, sex, age, dietetic conditions, and so on)
these findings cannot be univocally interpreted. However, tak-
en as a whole, these data seem to refer to a type of skeletal al-
teration ranging from a moderately low-turnover osteoporosis
to an osteomalacic trait. 
Pathophysiology
That primary hypercalciuria and bone disease are not a chance
association, but are strictly linked, is a well-established fact
based on several observations. The rate of urine calcium ex-
cretion was found to correlate with bone loss (10,17,20) and el-
evation in bone turnover markers (6,12,14,21). In addition, sev-
eral retrospective and prospective studies showed that thiazide
use is associated with a reduction in fracture incidence (22-27)
and an increase in bone density [28-30]. Although thiazides
may directly act on bone resorption (29,30), the reduction in re-
nal calcium excretion remains the most important contributing
factor to the improvement in bone density detected in thiazide-
treated subjects (28-30). 
Understanding the relationships between PH and bone loss
and the pathogenetic factors shared by the two conditions is
even more difficult. 
We will briefly review the role of bone, kidney, and intestine in
the pathogenesis of skeletal alteration of PH.
Bone
Since the revision of the types of PH proposed by Levy and
colleagues (37), the term “fasting hypercalciuria” has been
used to identify patients who could not lower or normalize their
urine calcium excretion appropriately after a restriction in di-
etary calcium consumption. As low bone density was more fre-
quently reported in these patients, the presence of some condi-
tions causing hypercalciuria and bone demineralization at the
same time was suggested.
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Table I - Bone mineral density (BMD) in patients with primary hypercalciuria.
Author (reference), year Measurement method Measurement site Result of BMD
Lawoyin et al. (3), 1979 SPA Radius fl N
Fuss et al. (4), 1983 SPA Radius fl
Pacifici et al. (5), 1990 QCT Spine fl
Bataille et al. (6), 1991 QCT Spine fl
Borghi et al. (7), 1991 DPA Spine fl
Pietschmann et al. (8), 1992 DEXA, SPA Spine, radius fl
Jaeger et al. (9), 1994 DEXA Spine, femur fl
Weisinger et al. (10), 1996 DEXA Spine, femur fl
Ghazali et al. (11), 1997 QCT Spine fl
Giannini et al. (12), 1998 DEXA Spine, femur fl
Misael da Silva et al. (13), 2002 DEXA Spine, femur fl
Tasca et al. (14), 2002 DEXA Spine, femur fl
Caudarella et al. (15), 2003 DEXA, QUS Radius, finger fl
Asplin et al. (16), 2003 DEXA Spine, femur fl
Vezzoli et al. (17), 2003 DEXA Spine, femur fl
DEXA: Dual Energy X-ray Absorptiometry; DPA: Dual Photon Absorptiometry; QCT: Quantitative Computed Tomography; QUS: Quantitative ultrasound; SPA:
Single Photon Absorptiometry.
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Pacifici et al. (5) firstly reported that some cytokines involved
in the mechanisms regulating bone resorption may be in-
volved in the pathogenesis of bone in patients with PH. They
found that monocytes from patients with fasting hypercalciuria,
but without the absorptive form, produced an exaggerated
amount of interleukin-1, a well-known very potent stimulator of
bone resorption processes (38), which in turn was correlated
with a significant degree of bone demineralization. The role of
cytokines in this setting was then confirmed by other reports.
Weisinger and coworkers (10) found that the production and
mRNA expression of IL-1a from unstimulated peripheral blood
mononuclear cells correlated with spinal bone loss in patients
with PH and nephrolithiasis. In addition, the same cells pro-
duced an increased amount of IL-1a , IL-6, and TNF-a as com-
pared to controls after stimulation with lipopolysaccharide
(LPS). Since all these cytokines are considered local media-
tors of bone resorption (39), the Authors concluded that bone
loss may largely depend upon these alterations in hypercalci-
uric patients with calcium stones. Similar results were ob-
tained by Ghazali et al. (11), who found that IL-1b , 6, TNF-
a, and GM-CSF from peripheral blood monocytes were in-
volved in the pathogenesis of bone loss in patients with PH.
The consistency of all these results undoubtedly strengthens
the importance of cytokines as pathogenetic factors of bone
loss in PH. However, it remains to be elucidated if an overpro-
duction of these cytokines from bone and bone marrow cells is
also present. Indeed, even if it is believed that an altered cy-
tokine secretion from peripheral mononuclear cells may in
some way reflect a similar pattern in bone marrow (40), all
these bone reabsorbing-substances are mainly considered lo-
cal regulating factors of cell differentiation and function (39). In
addition, no clear explanations were given for such an alter-
ation in cytokine secretion in patients with PH and no differ-
ences in IL-1b gene polymorphism were found between pa-
tients with or without PH (41). 
Other factors are thought to be involved in bone alteration in
PH. One of the most studied  features is the effect of protein in-
take in these patients. Excessive protein intake, especially of
animal origin, was found to sharply increase urine calcium ex-
cretion and bone resorption and lead to bone loss (42). The
main responsible mechanism for these effects is the acid load
produced by proteins, especially those rich in sulfur-containing
amino acids (42). Accordingly, it was demonstrated that sulfate
excretion and some markers of protein intake, such as urinary
or serum urea, well correlate with bone turnover markers and
density (6,8,9,43). In our study, we also found that a moderate
protein restriction was accompanied by a proportional reduc-
tion in calcium excretion and bone turnover markers in patients
with nephrolithiasis and PH (43). Since dietary protein excess
was repeatedly reported in hypercalciuric stone formers (42,43)
and hypersensitivity to protein effects on bone was also sug-
gested, normalization of protein intake is highly recommended
in hypercalciuric patients. 
No consistent data currently support the substantial role of cal-
ciotropic hormones in the pathogenesis of bone loss in PH.
Calcitriol was reported to be higher in PH patients than in con-
trols and it was observed that this hormone may induce an in-
crease in bone resorption (44). However, the elevation in cal-
citriol levels was more frequently described in patients with ab-
sorptive hypercalciuria, whose bone density levels are general-
ly normal or poorly diminished. In addition, Bataille et al. (6)
found that calcitriol levels have a protective rather than a dam-
aging effect on bone mass in patients with PH and kidney
stones. Apart from the very small proportion of patients that
can be classified as having renal hypercalciuria (37), PTH lev-
els are generally normal in PH patients and are not thought to
have a significant role in the pathogenesis of bone loss in this
setting. 
Intestine 
Although the classical distinction of PH in absorptive and fast-
ing hypercalciuria is still maintained, a wide overlap seems to
occur between the two forms. Besides, the intestinal function
plays a key role both in the pathogenesis of PH and in the de-
velopment or maintenance of bone disease. Indeed, as men-
ti ned above, some studies also reported a decrease in bone
density in patients with absorptive hypercalciuria (8). On the
other hand, an increased intestinal calcium absorption is fre-
quently present even in patients with fasting hypercalciuria
(45). Vezzoli and coworkers recently reconsidered the complex
relationships between intestine and bone in patients with PH in
a very interesting study (17). They assessed intestinal calcium
absorption in hypercalciuric patients through the method of sta-
ble strontium. They found that the greater the loss of bone min-
eral density, the larger the increase in intestinal calcium ab-
sorption, the latter being the best predictor of bone mass in a
multiple regression model. Since PTH values were similar in
hypercalciuric and normocalciuric stone formers, they speculat-
ed that this is not a compensatory phenomenon, but probably
the marker of a disturbed cell calcium transport, involving both
i testinal and bone tissue (17). This hypothesis would also be
i  keeping with the view that absorptive and fasting hypercalci-
uria may be different phenotypes and expressions of the same
d order (46). Although its nature is still poorly understood,
some genetic influences might be possible (47). 
Whatever the explanation for this increased intestinal calcium
absorption in patients with PH, the importance of this observa-
tion is further strengthened by considering that in the absence
of a proportional intestinal calcium hyperabsorption, the nega-
tive calcium balance observed in patients with fasting hypercal-
ciuria should be much larger than it actually is, with a tremen-
dous impact in terms of bone loss and fracture risk. Even if in-
testinal calcium absorption may largely vary, depending on di-
etary calcium intake, food quality, intestinal function, serum cal-
citriol, and so forth, approximately 4-5 mmol of calcium are ab-
s rbed daily through the gut and the same amount is eliminat-
d with the urines (47). In the presence of hypercalciuria, calci-
um balance may be maintained only at the expenses of skele-
t l tissue or by an increase in intestinal calcium absorption,
which may in turn limit bone loss. The restriction in dietary cal-
cium intake, which many hypercalciuric patients tend to do by
themselves or after medical prescription, is therefore a major
risk factor for bone loss in this setting. Indeed, it was clearly
se n that a reduction in calcium intake is associated with nega-
tive calcium balance and bone loss in hypercalciuric patients
(9,48,49). Some authors (48,49) reported this negative effect
after a calcium-restricted diet of 2-8 years, while Jaeger et al.
observed a significant reduction in bone density in hypercalci-
ric patients already after the first year of low calcium diet (9).
In addition, Curhan et al. (50) reported that dietary calcium re-
striction does not reduce the incidence of new kidney stones
but, in fact, it increases the risk of developing new symptomatic
renal calculi, at least in males. This seems to occur because of
the increase in intestinal oxalate absorption with a secondary
increase in its urinary excretion in the absence of calcium in
the colon. All these observations suggest that hypercalciuric
patients need to maintain an appropriate dietary calcium in-
t ke.
Kidney 
The presence of renal calcium leak is the basis for the so-
called renal hypercalciuria, which is characterized by increased
urine calcium, a tendency toward hypocalcemia, and a sec-
ondary increase in parathyroid hormone secretion. The latter is
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considered the main cause of bone loss in these patients (48).
However, the large revision of the pathogenetic aspects of pa-
tients with PH led to the observation that less than 5% of hy-
percalciuric patients suffer from a renal form of PH (37). As a
consequence, the importance of renal calcium leak as a patho-
genetic factor for bone loss in these patients was completely
reconsidered. 
However, some other aspects seem to link the kidney to the
complex relationships occurring between hypercalciuria and
bone. Increased urinary phosphate excretion was found in hy-
percalciuric patients as compared to normal subjects, irrespec-
tive of the presence of a true form of absorptive hypercalciuria
with renal calcium leak (51). It was suggested that an exces-
sive excretion of phosphate may be present in the majority of
patients with PH, then concurring to the development of the hy-
percalciuric state in the whole population of PH patients. Simi-
lar findings were reported by Prié et al. (52) in hypercalciuric
stone formers. They observed that the distribution of renal
phosphate threshold normalized for glomerular filtration rate
(TmPi) was quite different between patients and controls, with
hypercalciuric patients showing a decreased value of TmPi in
approximately 20% of cases. No assessment of bone status
was made in the two papers. However, it could be hypothe-
sized that the alteration in phosphate metabolism seen in these
patients may play a role also in the pathogenesis of bone dam-
age in hypercalciuric patients. Hereditary hypophosphatemic
rickets with hypercalciuria (HHRH) is a paradigm of this patho-
physiology (53). This disease shares some clinical aspects with
the disorder seen in the Npt2 knockout mice, carrying the dele-
tion of the gene of kidney-specific Na-Pi cotransporter, in which
a delay in bone mineralization is seen 21 days after birth.
These bone alterations may resemble those observed in hyper-
calciuric patients by histomorphometric studies (31-36), in
which an alteration in bone mineralization process was report-
ed. Accordingly, a mutation of NPT2 gene was found in
nephrolithiasic patients with decreased bone density by Prié
and coworkers (54). In conclusion, even if no clear evidence
supports the hypothesis that renal phosphate leak may be at
least in part responsible for bone disease in PH patients, this
research field appears as one of the most promising to better
elucidate the role of kidney in the pathogenesis of bone loss in
PH.
Conclusions
Bone disease is one of the most common clinical findings in
patients with PH, even though its importance seems to be cur-
rently underestimated. Most of the organs and tissues normally
involved in the control of calcium and phosphate metabolism
seem to take an active part in the pathogenesis of skeletal al-
terations. New insights in molecular medicine as well as larger
clinical studies will be helpful for a better understanding of this
very complex matter.
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